Skip to main content
NASDAQ:IOVA

Iovance Biotherapeutics Competitors

$25.82
+0.81 (+3.24 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.23
$27.00
50-Day Range
$25.01
$33.07
52-Week Range
$24.50
$54.21
Volume2.15 million shs
Average Volume1.83 million shs
Market Capitalization$3.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Competitors

Iovance Biotherapeutics (NASDAQ:IOVA) Vs. TECH, ARGX, QGEN, NVAX, RGEN, and NBIX

Should you be buying IOVA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Iovance Biotherapeutics, including Bio-Techne (TECH), argenx (ARGX), QIAGEN (QGEN), Novavax (NVAX), Repligen (RGEN), and Neurocrine Biosciences (NBIX).

Bio-Techne (NASDAQ:TECH) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bio-Techne and Iovance Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne03702.70
Iovance Biotherapeutics011002.91

Bio-Techne currently has a consensus target price of $396.1111, indicating a potential downside of 1.31%. Iovance Biotherapeutics has a consensus target price of $47.90, indicating a potential upside of 85.52%. Given Iovance Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Bio-Techne.

Volatility and Risk

Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Profitability

This table compares Bio-Techne and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Iovance BiotherapeuticsN/A-50.64%-45.64%

Earnings & Valuation

This table compares Bio-Techne and Iovance Biotherapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million21.13$229.30 million$3.86103.98
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-16.24

Bio-Techne has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

93.8% of Bio-Techne shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 3.8% of Bio-Techne shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bio-Techne beats Iovance Biotherapeutics on 8 of the 13 factors compared between the two stocks.

argenx (NASDAQ:ARGX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for argenx and Iovance Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
argenx071102.61
Iovance Biotherapeutics011002.91

argenx currently has a consensus price target of $297.8750, suggesting a potential upside of 9.39%. Iovance Biotherapeutics has a consensus price target of $47.90, suggesting a potential upside of 85.52%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than argenx.

Profitability

This table compares argenx and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
argenxN/AN/AN/A
Iovance BiotherapeuticsN/A-50.64%-45.64%

Earnings & Valuation

This table compares argenx and Iovance Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$78.17 million178.72$-182,520,000.00($4.73)-57.57
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-16.24

argenx has higher revenue and earnings than Iovance Biotherapeutics. argenx is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

54.2% of argenx shares are owned by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are owned by institutional investors. 9.9% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

argenx has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Iovance Biotherapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

QIAGEN (NYSE:QGEN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Profitability

This table compares QIAGEN and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
Iovance BiotherapeuticsN/A-50.64%-45.64%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for QIAGEN and Iovance Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN05902.64
Iovance Biotherapeutics011002.91

QIAGEN currently has a consensus target price of $60.76, suggesting a potential upside of 29.88%. Iovance Biotherapeutics has a consensus target price of $47.90, suggesting a potential upside of 85.52%. Given Iovance Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than QIAGEN.

Earnings & Valuation

This table compares QIAGEN and Iovance Biotherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion6.99$-41,460,000.00$1.4332.71
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-16.24

QIAGEN has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

QIAGEN has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

43.6% of QIAGEN shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 9.0% of QIAGEN shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

QIAGEN beats Iovance Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Iovance Biotherapeutics (NASDAQ:IOVA) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Risk & Volatility

Iovance Biotherapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.

Insider & Institutional Ownership

94.6% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 49.9% of Novavax shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 3.3% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Iovance Biotherapeutics and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iovance BiotherapeuticsN/A-50.64%-45.64%
Novavax-133.10%-1,346.17%-45.85%

Earnings & Valuation

This table compares Iovance Biotherapeutics and Novavax's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-16.24
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71

Novavax has higher revenue and earnings than Iovance Biotherapeutics. Novavax is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Iovance Biotherapeutics and Novavax, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iovance Biotherapeutics011002.91
Novavax11402.50

Iovance Biotherapeutics currently has a consensus price target of $47.90, indicating a potential upside of 85.52%. Novavax has a consensus price target of $216.3333, indicating a potential upside of 64.27%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Novavax.

Summary

Iovance Biotherapeutics beats Novavax on 10 of the 13 factors compared between the two stocks.

Repligen (NASDAQ:RGEN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Institutional and Insider Ownership

84.3% of Repligen shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 1.7% of Repligen shares are held by company insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Repligen and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repligen13.40%6.58%5.00%
Iovance BiotherapeuticsN/A-50.64%-45.64%

Earnings and Valuation

This table compares Repligen and Iovance Biotherapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$270.24 million34.94$21.41 million$1.07160.71
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-16.24

Repligen has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Repligen has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Repligen and Iovance Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repligen00503.00
Iovance Biotherapeutics011002.91

Repligen currently has a consensus target price of $222.75, indicating a potential upside of 29.54%. Iovance Biotherapeutics has a consensus target price of $47.90, indicating a potential upside of 85.52%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Repligen.

Summary

Repligen beats Iovance Biotherapeutics on 8 of the 12 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Risk & Volatility

Neurocrine Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Earnings and Valuation

This table compares Neurocrine Biosciences and Iovance Biotherapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.35$37.01 million$0.39242.56
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-16.24

Neurocrine Biosciences has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Neurocrine Biosciences and Iovance Biotherapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences071302.65
Iovance Biotherapeutics011002.91

Neurocrine Biosciences currently has a consensus price target of $127.8333, suggesting a potential upside of 35.13%. Iovance Biotherapeutics has a consensus price target of $47.90, suggesting a potential upside of 85.52%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Neurocrine Biosciences.

Profitability

This table compares Neurocrine Biosciences and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Iovance BiotherapeuticsN/A-50.64%-45.64%

Institutional & Insider Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Iovance Biotherapeutics on 10 of the 13 factors compared between the two stocks.


Iovance Biotherapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bio-Techne logo
TECH
Bio-Techne
1.8$401.37+1.3%$15.61 billion$738.69 million64.22
argenx logo
ARGX
argenx
1.1$272.30+4.0%$13.97 billion$78.17 million-57.57News Coverage
QIAGEN logo
QGEN
QIAGEN
1.7$46.78+0.6%$10.67 billion$1.53 billion57.75
Novavax logo
NVAX
Novavax
1.8$131.69+8.1%$9.76 billion$18.66 million-25.23Earnings Announcement
Analyst Report
Analyst Revision
Repligen logo
RGEN
Repligen
1.9$171.96+1.3%$9.44 billion$270.24 million209.71Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.60+2.8%$8.94 billion$788.10 million101.72Analyst Report
Unusual Options Activity
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$106.64+5.3%$8.08 billion$289.59 million-32.71Analyst Upgrade
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$126.09+2.2%$7.65 billion$73.99 million-48.68
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$76.70+6.8%$7.21 billion$10.68 million-41.68
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$53.90+4.1%$6.53 billion$26.68 million-24.39
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$43.03+2.9%$6.13 billion$195.99 million268.94Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Vir Biotechnology logo
VIR
Vir Biotechnology
1.4$42.21+6.3%$5.49 billion$8.09 million-17.89
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$34.54+2.7%$4.85 billion$85.07 million-36.36Analyst Report
Insider Selling
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99+1.7%$4.72 billion$503.70 million33.52Upcoming Earnings
Twist Bioscience logo
TWST
Twist Bioscience
1.6$92.68+4.9%$4.53 billion$90.10 million-24.71Analyst Revision
Gap Up
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$71.92+8.0%$4.50 billion$20,000.00-5.12Earnings Announcement
Analyst Report
Analyst Revision
Kodiak Sciences logo
KOD
Kodiak Sciences
1.7$84.05+4.4%$4.31 billionN/A-36.23Earnings Announcement
Analyst Upgrade
Analyst Revision
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$27.50+2.0%$3.89 billionN/A-12.91Analyst Report
Gap Up
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$73.10+6.5%$3.59 billionN/A-42.01Analyst Downgrade
News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$29.19+5.8%$2.64 billionN/A0.00Earnings Announcement
Vericel logo
VCEL
Vericel
1.1$50.77+5.7%$2.35 billion$117.85 million-5,077,000.00Analyst Report
Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$31.99+3.9%$2.35 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.5$25.55+7.8%$2.28 billionN/A-11.94Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.84+6.9%$2.28 billion$48.83 million-16.89
Editas Medicine logo
EDIT
Editas Medicine
1.6$33.22+5.5%$2.25 billion$20.53 million-19.09
NanoString Technologies logo
NSTG
NanoString Technologies
1.7$49.30+1.8%$2.23 billion$125.57 million-28.83Earnings Announcement
Analyst Report
Insider Selling
Gap Up
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.9$45.52+0.3%$2.05 billionN/A0.00Insider Selling
bluebird bio logo
BLUE
bluebird bio
1.8$30.32+3.3%$2.05 billion$44.67 million-2.76
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.62+4.1%$1.90 billion$31.43 million-4.53
Ocugen logo
OCGN
Ocugen
1.0$8.75+5.9%$1.73 billionN/A-5.91Earnings Announcement
Analyst Upgrade
Insider Selling
Replimune Group logo
REPL
Replimune Group
1.5$35.05+1.0%$1.63 billionN/A-19.80
AlloVir logo
ALVR
AlloVir
1.5$24.00+6.9%$1.56 billionN/A0.00Analyst Report
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.85+4.1%$1.56 billion$102.43 million-18.08Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.6$36.14+2.4%$1.54 billion$35.23 million-14.57Analyst Upgrade
News Coverage
Immunovant logo
IMVT
Immunovant
1.6$15.50+5.7%$1.52 billionN/A-12.02Unusual Options Activity
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$67.93+7.9%$1.51 billionN/A-45.90Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$34.84+2.2%$1.50 billionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Alector logo
ALEC
Alector
1.3$17.00+8.8%$1.36 billion$21.22 million-7.62News Coverage
Translate Bio logo
TBIO
Translate Bio
1.6$17.16+4.7%$1.29 billion$7.80 million-16.04
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.75+6.9%$1.27 billion$100.56 million0.00News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.99+1.8%$1.26 billionN/A-3.24Analyst Report
News Coverage
Curis logo
CRIS
Curis
1.3$13.57+3.7%$1.24 billion$10 million-16.55Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.13+8.2%$1.15 billion$356.07 million7.42Analyst Report
Cortexyme logo
CRTX
Cortexyme
1.1$36.77+6.6%$1.09 billionN/A-15.32Earnings Announcement
Analyst Upgrade
Insider Selling
News Coverage
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.50+3.4%$994.46 millionN/A-4.55Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$19.24+0.8%$988.53 millionN/A0.00Earnings Announcement
Scholar Rock logo
SRRK
Scholar Rock
1.5$27.92+1.9%$960.25 million$20.49 million-11.59Earnings Announcement
News Coverage
Gap Up
Sutro Biopharma logo
STRO
Sutro Biopharma
1.5$19.68+4.3%$907.50 million$42.74 million-218.67Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$6.99+3.7%$906.88 million$32.16 million-7.94
Passage Bio logo
PASG
Passage Bio
1.8$15.50+1.9%$836.64 millionN/A0.00
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.